Table 2.
Univariate analysis of factors influencing the overall survival of 78 MF-CCA patients
| Factors | Survival time (months)
|
P | |||
|---|---|---|---|---|---|
| Median | 95% CI of median | 3 years (%) | 5 years (%) | ||
| Sex | |||||
| Male (n=33) | 14.70 | 7.89–21.50 | 21.2 | 18.2 | 0.719 |
| Female (n=45) | 10.82 | 5.85–15.79 | 24.4 | 15.0 | |
| Age | |||||
| ≦60 (n=38) | 12.89 | 4.45–21.33 | 26.3 | 21.1 | 0.505 |
| >60 (n=40) | 12.99 | 7.23–18.74 | 20.0 | 12.0 | |
| Symptoms | |||||
| Negative (n=12) | 37.71 | 4.78–70.63 | 58.3 | 41.7 | 0.006 |
| Positive (n=66) | 10.45 | 5.84–15.07 | 16.7 | 11.9 | |
| AST (IU/L) | |||||
| ≦34 (n=39) | 13.32 | 9.53–17.10 | 30.8 | 22.8 | 0.197 |
| >34 (n=38) | 10.72 | 2.28–19.16 | 15.8 | 10.5 | |
| ALT (IU/L) | |||||
| ≦36 (n=40) | 12.99 | 6.41–19.56 | 25.0 | 19.7 | 0.625 |
| >36 (n=31) | 14.70 | 7.81–21.58 | 19.4 | 9.7 | |
| ALP (IU/L) | |||||
| ≦94 (n=23) | 23.90 | 11.65–36.15 | 39.1 | 29.8 | 0.009 |
| >94 (n=52) | 9.11 | 4.92–13.29 | 15.4 | 5.0 | |
| Bil (total) (mg/dL) | |||||
| ≦1.3 (n=64) | 12.99 | 6.41–19.56 | 25.0 | 16.9 | 0.581 |
| >1.3 (n=14) | 10.72 | 0.00–22.23 | 14.3 | 14.3 | |
| Albumin (g/dL) | |||||
| ≦3.5 (n=22) | 4.70 | 3.11–6.29 | 18.2 | 13.6 | 0.063 |
| >3.5 (n=49) | 19.04 | 13.31–24.76 | 24.5 | 15.9 | |
| Serum CEA (ng/dL) | |||||
| ≦5 (n=25) | 18.51 | 2.09–34.93 | 40.0 | 27.0 | 0.043 |
| >5 (n=31) | 10.29 | 4.05–16.53 | 6.5 | 6.5 | |
| Margin | |||||
| Negative (n=54) | 19.43 | 14.97–23.89 | 33.3 | 23.8 | <0.001 |
| Positive (n=24) | 4.41 | 2.43–6.38 | 0.0 | 0.0 | |
| Size | |||||
| ≦5 cm (n=32) | 19.99 | 13.75–26.23 | 37.5 | 30.7 | 0.006 |
| >5 cm (n=43) | 9.11 | 1.97–16.25 | 14.0 | 7.0 | |
| Lymph node | |||||
| Negative (n=47) | 19.89 | 16.71–23.07 | 29.8 | 18.7 | 0.063 |
| Positive (n=29) | 10.45 | 0.00–22.71 | 13.8 | 13.8 | |
| Histology | |||||
| Well (n=2) | 2.73 | NA | 0.0 | 0.0 | 0.207 |
| Moderate (n=41) | 13.84 | 7.45–20.23 | 22.0 | 17.1 | |
| Poor (n=33) | 12.99 | 5.25–20.72 | 27.3 | 17.3 | |
| Others (n=2) | 4.37 | NA | 0.0 | 0.0 | |
| SPARC expression | |||||
| Tumor positive and stromal negative (n=37) | 17.16 | 9.21–25.12 | 29.7 | 27.0 | 0.022 |
| Others (n=41) | 8.25 | 3.88–12.62 | 17.1 | 6.5 | |
| Post-op chemotherapy | |||||
| Without (n=33) | 5.65 | 2.47–8.84 | 30.3 | 23.9 | 0.937 |
| With (n=45) | 14.70 | 9.64–19.75 | 17.8 | 11.1 | |
| Post-op radiotherapy | |||||
| Without (n=68) | 13.32 | 8.27–18.36 | 26.5 | 18.9 | 0.071 |
| With (n=10) | 6.97 | 5.29–8.65 | 0.0 | 0.0 | |
Abbreviations: MF-CCA, mass-forming cholangiocarcinoma; AST, aspartate aminotransferase; IU, international unit; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Bil, bilirubin; CEA, carcinoembryonic antigen; SPARC, secreted protein acidic and rich in cysteine; op, operation.